Guerbet : Q1 2020 sales in line - it is difficult to make forecasts for after June - target price adjusted to € 30.6 vs € 34
>Q1 in line, but with a slightly more contrasted mix than expected - Q4 sales came in at € 199.2m, i.e. +1% and +1.4% at constant currencies (cc). X-ray sales have increased in accordance with management’s latest indications (€ 107m/+4.3%), MRI sales have consolidated (€ 64.4m/-3%) and RIT sales have sharply increased (€ 19.2m/+15%), pursuing its market share gains (ramp-up effect). The growth difference between Europe and the RoW is higher than we expected. In Europe...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.